Kornimate/medical-research-clean huggingface dataset:
clinical values of automated electronic alert for acute kidney injury

Conditions: Acute Kidney Injury

Summary: acute kidney injury (aki) is common, serious and expensive.it is associated with significant mortality, morbidity and increased length of hospital stay.to improve clinical outcomes of aki by early detection and timely referral to the renal,the investigators developed an electronic alert system which identifies all cases of aki occurring in patients over 18 years.the system was also designed to collect data on aki incidence one of the biggest tertiary hospital in china.

a prospective, randomly controlled cohort study will be conducted agmong the patients with aki who are detected by the use of aki sniffer. the investigators chose to assess all inpatient serum creatinine results using a combination of "kdigo" criteria. the investigators randomly divided the patients into two groups: 1. usual care : patients will receive standard clinical care by the primary physicians 2. aki alert : an aki alert will be sent to the the doctor in charge. our team of kidney experts would give a suggestion if the the doctor in charge issue consultation applications.

Eligibility criteria:
inclusion criteria: * adult patients with an alert for aki(based on kdigo guidelines) exclusion criteria: * patients already on dialysis for aki at the time of alert * patients with end stage renal disease * patients \<18 years of age * patients dissenting from participation according to the ethics application

Keywords: acute kidney injury medication alert systems
assessment of small airways involvement in asthma (atlantis)

Conditions: Asthma

Summary: multinational, multicentre, non-pharmacological intervention, cross-sectional and longitudinal study.

large non pharmacological studies on small airways disease

Eligibility criteria:
asthmatic patient inclusion criteria 1. male or female patients aged ≥ 18 and ≤ 65 years, who have signed an informed consent form 2. clinical diagnosis of asthma f 1. positive response to methacholine challenge test 2. positive response to a reversibility test or 3. peak flow variability (i.e. highest - lowest pef over the day/mean value of the two, × 100) \> 20% or 4. documented response (defined as δfev1 ≥ 12% and ≥ 200 ml) after a cycle (e.g., 4 weeks) of regular maintenance anti-asthma treatment. 3. patients with stable asthma. 4. current smoker, ex-smoker or lifelong non-smoker healthy subject inclusion criteria 1. male or female patients aged ≥ 18 and ≤ 65 years 2. no clinical history of asthma or copd 3. current smoker, ex-smoker or lifelong non-smokers 4. normal spirometry 5. normal airways responsiveness asthmatic patient exclusion criteria 1. cigarette smoking \> 10 packyears 2. diagnosis of copd 3. asthma exacerbation in the 8 weeks prior to baseline visit 4. clinical or functional uncontrolled respiratory, haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease, or any condition that might compromise the results or interpretation of the study. 5. pregnant or lactating women 6. participation in an interventional clinical trial \<12 weeks preceding baseline visit 7. inability to comply with study procedures. 8. alcohol or drug abuse. healthy subject exclusion criteria 1. cigarette smoking history \> 10 packyears 2. diagnosed upper and/or lower respiratory disease(s). 3. clinical or functional uncontrolled haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease, or any condition that mightp compromise the results or interpretation of the study. 4. pregnant or lactating women 5. participation in an interventional clinical trial \<12 weeks preceding baseline visit 6. inability to comply with study procedures. 7. alcohol or drug abuse.
l-carnitine l-tartrate in preventing peripheral neuropathy caused by chemotherapy in women with metastatic breast cancer

Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Neurotoxicity

Summary: rationale: l-carnitine l-tartrate may prevent peripheral neuropathy caused by chemotherapy. purpose: this randomized clinical trial is studying how well l-carnitine l-tartrate works in preventing peripheral neuropathy caused by chemotherapy in women with metastatic breast cancer.

objectives: * to evaluate the tolerability and usefulness of the dietary supplement, l-carnitine l-tartrate, in the prevention of chemotherapy-induced peripheral neuropathy in women with metastatic breast cancer. outline: patients are randomized to 1 of 2 treatment arms. * arm i: patients receive oral l-carnitine l-tartrate twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy. * arm ii: patients receive oral placebo twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy. patients complete questionnaires periodically to assess neuropathy, pain, fatigue, sleep, and activities of daily living. after completion of study treatment, patients are followed at 4 weeks and then every 3 months thereafter.

Eligibility criteria:
disease characteristics: * diagnosis of breast cancer * metastatic disease * scheduled to receive ≥ 1 of the following chemotherapy drugs: * paclitaxel * docetaxel * capecitabine * gemcitabine hydrochloride * concurrent enrollment in the university of minnesota study "population pharmacokinetics and pharmacogenetics of gemcitabine in adult patients with solid tumors" (human subjects code 0508m72989) required * albumin-bound paclitaxel (abraxane) * doxorubicin hydrochloride patient characteristics: * life expectancy ≥ 6 months * serum creatinine \< 2.0 mg/dl * not pregnant or nursing * fertile patients must use effective contraception * no history of seizures * no uncontrolled hypertension * no history of stroke * no malabsorption syndrome * no cognitive impairment * no history of psychiatric disability affecting informed consent or compliance with drug intake * able to take oral medication * able to complete questionnaire(s) alone or with assistance prior concurrent therapy: * see disease characteristics * no concurrent warfarin * no concurrent radiotherapy

Keywords: neurotoxicity chemotherapeutic agent toxicity stage iv breast cancer recurrent breast cancer
risk assessment and mechanism analysis of intracranial multiple aneurysm instability based on high-resolution magnetic resonance, imaging histology and hemodynamics

Conditions: Arterial Aneurysm Wall Enhancement on HRMRI

Summary: this project proposes to establish a prospective cohort of mia based on a preexisting multicenter mia database and to combine multidimensional methods such as high-resolution magnetic resonance, hemodynamics, ambulatory blood pressure, and imaging histology to study aneurysm instability.


Eligibility criteria:
inclusion criteria: * age 18-80 years old, male or infertile female; * diagnosed as ia (intracranial aneurysm) through cta, mra, or dsa; and it is suitable for endovascular intervention treatment * the patient and/or their legal representative or guardian fully understand the research purpose, voluntarily participate and sign informed consent books; * patients willing to cooperate with high-resolution magnetic resonance imaging. * patients willing to follow up and evaluate according to clinical research protocol requirements exclusion criteria: * avm (arteriovenous malformation), moyamoya disease, or davf (dural arteriovenous fistula) related aneurysms; * patients with contraindications for high-resolution magnetic resonance imaging; * participants in clinical trials of other drugs or medical devices; * patients with severe underlying diseases and extremely poor clinical conditions who cannot tolerate general anesthesia surgery; * patients with poor compliance and inability to cooperate with follow-up; * possible or clear history of severe allergy to contrast agents; * patients with a life expectancy of less than 2 years; * women who are breastfeeding and preparing for pregnancy during the study period
reference ranges for the cough responsiveness to inhaled mannitol

Conditions: Cough

Summary: cough is the most common reason why people seek medical attention in developed countries. the main mechanisms for prolonged cough are hypersensitivity of the cough reflex arc, sputum production, and constriction of the airway smooth muscles. recognition of the mechanism in each cough patient is essential for the efficient management of prolonged cough. at present, there are no feasible tests for everyday clinical work to recognize cough reflex arc hypersensitivity. mannitol test was originally developed for asthma diagnostics. we have recently shown that it can also be used to investigate hypersensitive cough reflex arc. the purpose of the present study is to create reference ranges for normal cough responsiveness to inhaled mannitol. without them, the test cannot be utilized in everyday clinical work. for that purpose we will perform mannitol test in 140 subjects, who are at least 18 years old and without any chronic respiratory symptoms or disorders. the subjects will be recruited in three centers: university of eastern finland and: john hunter hospital in australia.the material will be collected 1.9.2021-31.12.2023. we apply funding for both personnel and material expences, to carry out this study.


Eligibility criteria:
inclusion criteria: * age 18 years or older * capable to understand the purpose of the study * female/male ratio approximately 50%/50% in both of the following age groups: * 50% aged 18- 50 yrs, and 50 % aged 51 - 90 years exclusion criteria: * current daily smoking * ex-smoking with a greater than 10 pack years' daily smoking history or with stopping of daily smoking less than one year ago * pregnancy and breastfeeding * a doctor's diagnosis of any respiratory diseases, including both upper and lower airway diseases, lung parenchymal diseases and the sleep apnoea syndrome * a doctor's diagnosis of gastro-oesophageal reflux disease or symptoms suggestive of it * current use of angiotensin-converting enzyme inhibitors * upper respiratory tract infection ('flu') within 4 weeks * any current (within 4 weeks) cough 8 * chronic (over 2 months' duration) cough during the last 12 months * wheezing during the last 12 months * attacks of shortness of breath or cough at night during the last 12 months * symptoms of rhinitis in a prolonged fashion during the last 12 months * heartburn or regurgitation once a week or more often during the last 3 months * abnormal anatomy of the respiratory organs, which may affect the deposition of the mannitol powder * any previous operations to the respiratory organs that can affect the deposition of the mannitol powder * unable to provide written informed consent to participate in the study
a study to assess the efficacy of inhaled corticosteroid (ics) therapy in moderate-severe bronchial asthma

Conditions: Bronchial Asthma

Summary: the purpose of this study is to investigate/assess the treatment of moderate to severe asthmatics with inhaled corticosteroid.


Eligibility criteria:
inclusion criteria: * male and/or female moderate to severe asthmatic patients, from 18-75 years of age. * moderate to severe asthma, according to the gina guidelines, for at least one year with no exacerbations requiring hospitalization and/or oral steroids within the previous three months. * no concomitant lung disease or significant medical conditions * fluticasone propionate 500mcg daily or greater, or equivalent (mometsaone 800 mcg, triamcinolone 2000 mcg, flunisolide 2000 mcg, budesonide dpi 800 mcg, beclomathasone hfa 500 mcg, beclomethasone cfc 1000 mcg, forced expiratory volume in 1 second (fev1) at screening will be ≥ 70% of the normal predicted. * evidence of asthma, demonstrated by one of the following: historical evidence confirmed by their treating physician or demonstration of ≥ 12% reversibility of fev1 using a standard dose of salbutamol (up to 400 µg) within 30 minutes. * female subjects of child bearing potential must be using two forms of contraception or postmenopausal women must have no regular menstrual bleeding for at least 2 years prior to inclusion. * body mass index between 18 and 30. body weight should be less than 100 kg. exclusion criteria: * smokers * concomitant medications: except for short- and long-acting β-agonists and medication which may be required to treat adverse events, all other medications, other than study drug should be avoided from screening until all of the study completion evaluations have been conducted. paracetamol is acceptable. * medical conditions: history of clinically significant drug allergy; any significant medical condition. for example, a history of any pulmonary disorder other than asthma. * any surgical or medical condition which might significantly alter the distribution, metabolism or excretion of the drug. * participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation. * donation or loss of 400 ml or more of blood within 8 weeks prior to dosing or longer if required by local regulation. * significant illness within the two weeks prior to dosing. * a past personal or close family medical history of clinically significant cardiac abnormalities * history of history of fainting, orthostatic hypotension, sinus arrhythmia, etc. * a known hypersensitivity to fluticasone propionate or drugs similar to fluticasone propionate. * history of immunocompromise, including a positive hiv test result. * a positive hepatitis b surface antigen (hbsag) or hepatitis c test result. * history of drug or alcohol abuse within the 12 months prior to dosing other protocol-defined inclusion/exclusion criteria may apply

Keywords: markers, inflammation, optimal, sub-optimal, corticosteroid, bronchial asthma
freestyle libre flash glucose monitoring system post approval study for pediatric patients

Conditions: Diabetes Mellitus

Summary: this is a prospective, multi-center, non-randomized, single-arm, post-approval study of the freestyle libre flash glucose monitoring system intended to characterize the safety of the libre flash glucose monitoring system when used in pediatric patients with diabetes.

up to 400 pediatric subjects aged 4-17 years with type 1 or type 2 diabetes, who require daily blood glucose monitoring to manage their diabetes, will be enrolled to obtain at least 314 subjects who complete the final visit. subjects and/or their caregivers will utilize capillary smbg for managing diabetes for 6 months (control phase) followed by diabetes management using freestyle libre for 6 months (intervention phase). subjects and/or their caregivers will maintain a diary/log book of adverse events during each phase. assessment of adverse events will occur via self reporting at each monthly visit and/or phone call.

Eligibility criteria:
inclusion criteria: * subject must be 4 - 17 years of age. * subject must have a diagnosis of type 1 or type 2 diabetes mellitus for at least 3 months prior to enrollment. * subject is currently using smbg for managing their diabetes. * subject and/or caregiver must be able to read and understand english . * in the investigator's opinion, the subject and/or caregiver must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol. * subject and/or caregiver must have access to an internet connected computer for uploading data from the blood glucose meter and freestyle libre system. * subject must have an overnight companion (caregiver 18 years or older) present in the same home during participation of the study. * subject and/or parent or guardian must be willing and able to provide written signed and dated informed consent and assent when appropriate. exclusion criteria: * subject and/or caregiver is a member of the site staff. * subject is currently using or has previously used a continuous glucose monitoring system for managing their diabetes * subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin. * subject is known to be pregnant or is attempting to become pregnant at the time of enrollment. * subject is on dialysis at the time of enrollment. * subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff. * subject currently is participating in another clinical trial. * subject is unsuitable for participation due to any other cause as determined by the investigator.
a compassionate use (cu) program of odronextamab

Conditions: Relapsed or Refractory (R/R) Follicular Lymphoma (FL); Diffuse Large B-Cell Lymphoma (DLBCL); B-Cell Non-Hodgkin Lymphoma (NHL); High-Grade B-Cell Lymphoma (HGBCL)

Summary: provide compassionate use of odronextamab


Eligibility criteria:
temporally optimized patterned stimulation (tops®) deep brain stimulation (dbs) for the treatment of parkinson's disease

Conditions: Parkinson Disease

Summary: this study will test newly developed stimulation settings called temporally optimized patterned stimulation or tops, which can be used with an already implanted deep brain stimulation system. the purpose of this study is to determine if tops dbs can improve parkinson's symptoms compared to standard dbs.


Eligibility criteria:
key inclusion criteria: * diagnosed with parkinson's disease * implanted with unilateral or bilateral subthalamic dbs system to treat parkinson's disease at least 6 months prior to the study date * responds to dbs by having demonstrated a minimum improvement in motor score key exclusion criteria: * score of \<24 on the mini mental status exam * abuses drugs or alcohol * pregnant * history of significant cardiovascular, pulmonary, musculoskeletal, metabolic, or other neurological disorders (i.e. epilepsy, stroke) * prisoners, employees that report to investigators

Keywords: deep brain stimulation
impact of baduanjin qigong exercise on fatigue in patients with nsclc undergoing adjuvant chemotherapy

Conditions: Fatigue

Summary: baduanjin，a type of qigong which belongs to aerobic exercise, is very popular in china. there is increasing evidence to support its positive effects on health outcomes in various groups of people with physical and mental disorders. in college students, it may enhance cardio respiratory function, lower limb function, and flexibility compared with usual exercise. however, there is no previous relevant randomized controlled trials on the health promoting effects of baduanjin exercise in targeted fatigued lung cancer patients. lung cancer survivors can experience fatigue due to multiple reasons that can strongly impact their quality of life throughout the remainder of their life. therefore, this randomized controlled trial in china was designed to assess the health promoting effects of baduanjin exercise in fatigued lung cancer patients with the expectation of improvement in physical and psychological health.


Eligibility criteria:
inclusion criteria: * this trial aims to enroll 18- to 75-year-old patients expected to survive \> 3 months and with a zubrod performance status of 0 to 2. all patients must have diagnosed as lung cancer and have at least one cycle of adjuvant chemotherapy. enrolled patients should have a minimal esas fatigue as 3. other inclusion criteria are lack of leptomeningeal disease, adequate hepatorenal function and blood counts (red blood cells, \>3.0 \* 1012/l; white blood cells, \> 3.5 \* 109/l; absolute neutrophil count, \> 1.5 \* 109/l; platelets, \> 100 \* 109/l; hemoglobin \> 90 g/l). exclusion criteria: * children
wecare: a behavioral intervention for dementia caregivers

Conditions: Caregiver Burden; Caregiver Stress Syndrome

Summary: this study aims to pilot test a culturally tailored behavioral intervention called "wecare" to enhance caregiving mastery and improve psychosocial wellbeing of chinese american family caregivers of persons with alzheimer's disease and related dementia.

the investigators propose to test a culturally tailored mhealth behavioral intervention to enhance caregiving mastery and improve psychosocial wellbeing among chinese american family caregivers of persons living with alzheimer's disease and related dementia. this intervention, wellness enhancement for caregivers (wecare), will be delivered via wechat, a social media app highly popular among chinese americans. about 45 participants will be recruited for the pilot test. participants will complete a baseline survey, receive 7-week wecare program on their wechat accounts, complete a follow-up survey 12 weeks after the baseline, and then a qualitative interview on zoom.

Eligibility criteria:
inclusion criteria: 1. 21 years or older, 2. self-identified as chinese or chinese american, 3. speak and read chinese (mandarin or cantonese), 4. own a smartphone and use wechat, 5. living in washington dc metropolitan, and 6. currently care for a family member with adrd and provide care for at least 10 hours a week. exclusion criteria: 1. do not read or speak chinese, 2. care-recipient is in hospice care or have a life expectancy less than 6 months, 3. signs of severe intellectual deficits or psychotic disorders, or 4. unable to provide informed consent.
haloperidol, droperidol, ondansetron in cannabis hyperemesis

Conditions: Cyclic Vomiting Syndrome

Summary: the purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications, treatment failures and complications/side effects.


Eligibility criteria:
inclusion criteria: * adult patients with clinical diagnosis of cyclic vomiting in the ed exclusion criteria: * pregnancy, allergy to any of the study medicines